New anxiety drug shows promise in early trial
NCT ID NCT06653296
First seen Jun 25, 2026 · Last updated Jun 26, 2026 · Updated 1 time
Summary
This study tested a new drug called ENX-102 in 38 adults with generalized anxiety disorder. Participants received either a low, mid, or high dose of ENX-102 or a placebo for six weeks. The goal was to check safety and find the best dose. The trial is now complete.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
ENX-102
What this could lead to
If successful, this could point toward a new treatment option for generalized anxiety disorder with a potentially better safety or tolerability profile.
What could go wrong
This is a small, early-phase trial with only 38 participants. The drug may not prove more effective than placebo, and side effects could limit its use.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for GENERAL ANXIETY DISORDER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
MAC Clinical Research
Liverpool, UK, United Kingdom
-
MAC Clinical Research
Blackpool, United Kingdom
-
MAC Clinical Research
Manchester, United Kingdom